News

The drug, which is a solution formulation, has been approved in 200mg, 1gm and 2gm with a concentration of 38 mg/ml strength. The company expects to roll out

As per the agreement, the holders of Emdeon common stock are expected to get around $19 per share in cash. Following the merger, Emdeon will become a privately

Firefly will utilize the grant to braden its production capacity and also to assess its microRNA assay. MicroRNAs are a class of biomarkers which are used as indicators

Dyadic’s net loss was $736,204, or $0.02 loss per diluted share, compared to $1.41m, or $0.05 per diluted share, for the same period in 2010. The company’s loss

The trial aims to compare the effectiveness and safety of conventional therapy treatment plus ecallantide to conventional therapy treatment plus placebo in 176 patients recruited at 40 US

Botanical Science Technologies will become the subsidiary of IMD Companies. The marketing plan includes on-line sales services, direct distribution through participating weight-loss centers and licensed consignment agreements with

Lebrikizumab, developed by Genentech Research and Early Development, is a humanized monoclonal antibody designed to block the IL-13 cytokine and reduce inflammation in the lung. The study, which

For the second quarter of 2011, the company has posted net income of $56.36m, or $0.17 per diluted share, compared to $33.97m, or $0.21 per diluted share, for

The multicenter, open-label, randomized study was designed to assess the safety and tolerability of hGH-CTP in growth hormone deficient adults. The data demonstrated that a single weekly injection